Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Obatoclax |
| Synonyms | |
| Therapy Description |
Obatoclax (GX015-070) is a pan-BCL2 family inhibitor, which leads to induction of tumor cell apoptosis (PMID: 18040043, PMID: 17332241, PMID: 32367199). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Obatoclax | GX015-070 | BCL2 Family Inhibitor 6 | Obatoclax (GX015-070) is a pan-BCL2 family inhibitor, which leads to induction of tumor cell apoptosis (PMID: 18040043, PMID: 17332241, PMID: 32367199). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NRAS mutant | Advanced Solid Tumor | sensitive | Obatoclax | Preclinical | Actionable | In a preclinical study, obatoclax decreased proliferation in human tumor cell lines with NRAS mutation in culture (PMID: 22460902). | 22460902 |
| BRAF mutant | Advanced Solid Tumor | sensitive | Obatoclax | Preclinical | Actionable | In a preclinical study, obatoclax decreased proliferation in human tumor cell lines with BRAF mutation in culture (PMID: 22460902). | 22460902 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|